Showing results (21-30 of 32) with videos related to
Sort By:
Pageof 4
Journal of the National Cancer Institute|January 25, 2022
ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic ImplicationsTony El Jabbour, Maksym Misyura, Darren Cowzer, et al.Nature|July 6, 2018
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesionsMichal Zimmermann, Olga Murina, Martin A M Reijns, et al.Nature Biotechnology|November 28, 2017
Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiencyMarella D Canny, Nathalie Moatti, Leo C K Wan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b ResultsEzra Y Rosen, Timothy A Yap, Elisa Fontana, et al.Molecular Cancer Therapeutics|December 16, 2021
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP InhibitorsAnne Roulston, Michal Zimmermann, Robert Papp, et al.Cell|July 11, 2020
A Genetic Map of the Response to DNA Damage in Human CellsMichele Olivieri, Tiffany Cho, Alejandro Álvarez-Quilón, et al.Nature|July 20, 2018
The shieldin complex mediates 53BP1-dependent DNA repairSylvie M Noordermeer, Salomé Adam, Dheva Setiaputra, et al.Research Square|August 6, 2025
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivityJohn Maris, Isabel Soria-Bretones, Matias Casás-Selves, et al.Journal of Medicinal Chemistry|February 1, 2024
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)W Cameron Black, Abbas Abdoli, Xiuli An, et al.Journal of Medicinal Chemistry|May 16, 2025
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 InhibitorFrédéric Vallée, Matias Casás-Selves, Monica Bubenik, et al.Pageof 4